Delta Dental of Michigan, Delta Dental of North Carolina and OraLiva Inc. Announce Multi-State Launch of AI-Powered Oral Cancer Test
Read More
DURHAM, N.C., October 30, 2026 – OraLiva, Inc., an early cancer detection company developing AI-enabled cytology diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to ORAL ONC-InCYT, an investigational test designed to help clinicians assess suspicious white or red oral lesions. ORAL ONC-InCYT analyzes cells collected from […]
DURHAM, NC, October 12, 2026: OraLiva, a mission-driven diagnostics company dedicated to catching cancer earlier, today announced that it has been named a Finalist in the 2026 Digital Health & AI Awards in the Rising Star track, Cancer, Screening & Early Detection category. The Digital Health & AI Awards recognize companies and innovations helping shape […]
Oral cancer is one of the few cancers dentists see coming and still, too often, catch too late. Most cases are visible during a routine exam, yet nearly 3 in 4 aren’t identified until a late stage, when five-year survival drops from roughly 88% to just 37%. The problem isn’t awareness. It’s that dental teams […]
OraLiva is pleased to announce a collaboration with Rovers Medical Devices, a global leader in medical sampling devices, to support the OraLiva’s AI-powered oral cytology test. As part of the collaboration, OraLiva will utilize Rovers’ Orcellex® brush technology, which is designed to collect high-quality transepithelial cellular samples. These samples are then analyzed using OraLiva’s advanced […]
New collaboration covers non-invasive cytology and AI risk-stratification to dentists across Michigan, Ohio, Indiana, and North Carolina Durham, NC — January 15th, 2026 — Delta Dental Plan of Michigan, Inc. Delta Dental Plan of Ohio, Inc., Delta Dental Plan of Indiana, Inc., (collectively “DDMI”) and Delta Dental of North Carolina(“DDNC”)[1] have reaffirmed their commitment to […]
